{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7089,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/16",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-16",
      "loopMatches": [
        {
          "to": 20,
          "from": 15,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
          "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        },
        {
          "to": 20,
          "from": 13,
          "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "testimonial",
      "function": "illustrate_case",
      "notes": "The slide uses a before-and-after visual comparison to demonstrate clinical efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/17",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-17",
      "loopMatches": [
        {
          "to": 20,
          "from": 15,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
          "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        },
        {
          "to": 20,
          "from": 13,
          "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Swimmer plot visualization of clinical trial data (Trial LXH254X2102).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/18",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-18",
      "loopMatches": [
        {
          "to": 20,
          "from": 15,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
          "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        },
        {
          "to": 20,
          "from": 13,
          "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/19",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-19",
      "loopMatches": [
        {
          "to": 20,
          "from": 15,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
          "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        },
        {
          "to": 20,
          "from": 13,
          "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Swimmer plot visualization of clinical trial data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/20",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-20",
      "loopMatches": [
        {
          "to": 20,
          "from": 15,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
          "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
          "position": 0,
          "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Agitate (Make it worse)",
          "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
          "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Development",
          "parentBeatSlug": "development"
        },
        {
          "to": 20,
          "from": 13,
          "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "traction",
      "function": "analyze_data",
      "notes": "The diagram uses a tree structure to categorize patient outcomes (off treatment vs on treatment, further broken down by SD and PR).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/21",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "traction",
      "function": "analyze_data",
      "notes": "The chart displays adverse events occurring in >=10% of patients (n=15).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/22",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/23",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a biological signaling pathway map to justify combination therapy strategy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/24",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/25",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/26",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The diagram shows the signaling pathway with specific drug targets highlighted.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/27",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Data shows tumor volume over time for various treatment groups including monotherapy and combinations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/28",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes waterfall plot (left) and swimmer plot (right) with specific response rates and disease control rates.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/29",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Data cut 23MAR2023. Table shows frequency of specific adverse events by severity grade and dosage cohort.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/30",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a process-oriented flow to demonstrate clinical validation milestones.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/31",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses arrows to visually indicate performance superiority of ERAS-601 over RMC-4550.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/32",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Data presented as tumor volume over time (days) with error bars representing SEM.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/33",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "testimonial",
      "function": "illustrate_case",
      "notes": "Includes RECIST 1.1 criteria reference and specific tumor measurements over time.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/34",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/35",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-35",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows the EGFR signaling pathway leading to MAPK and PI3K pathways.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/36",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-36",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/37",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/38",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart shows a statistically significant (***) improvement in survival for the ERAS-801 group compared to the control and other standard-of-care inhibitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/39",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide presents four separate survival plots (HK301, GS025, HK336, GS187) comparing vehicle control to ERAS-801 treatment.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/40",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a waterfall plot to show individual model responses, with a heatmap below for patient characteristics (recurrence, sex, methylation status).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/41",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a table format to communicate a product development roadmap.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/42",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-42",
      "loopMatches": [
        {
          "to": 44,
          "from": 42,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "4f36a34d-ac49-471d-8a8d-29994cfbabb4",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 1,
          "objective": "What are the potential quick wins and big bets for Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 42,
          "beatId": "a69b3bd5-ee9f-43e1-8899-1c300b6881b2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/43",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-43",
      "loopMatches": [
        {
          "to": 44,
          "from": 42,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "4f36a34d-ac49-471d-8a8d-29994cfbabb4",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 1,
          "objective": "What are the potential quick wins and big bets for Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 42,
          "beatId": "a69b3bd5-ee9f-43e1-8899-1c300b6881b2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "closing_ask",
      "function": "state_next_steps",
      "notes": "Features the Lorenz attractor graphic, which is a signature visual for Erasca.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/44",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-44",
      "loopMatches": [
        {
          "to": 44,
          "from": 42,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "4f36a34d-ac49-471d-8a8d-29994cfbabb4",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 1,
          "objective": "What are the potential quick wins and big bets for Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 44,
          "from": 42,
          "beatId": "a69b3bd5-ee9f-43e1-8899-1c300b6881b2",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "The document outlines Erasca's anticipated key milestones and clinical trial readouts.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-8a55-750a-8008-603750933d71",
      "docSlug": "da8608bdf4ad385699d1340db7dce185",
      "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a structured comparison between preclinical and clinical assets, with a specific callout for the lead asset (Naporafenib).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/45",
      "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
      "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}